Navigation Links
Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
Date:11/27/2011

LAGUNA NIGUEL, Calif., Nov. 28, 2011 /PRNewswire/ --  Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the initiation of patient enrollment in the second of two pivotal studies in the Company's OBI-1 Accur8 clinical trial program.  In the newly initiated clinical study, OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product, will be evaluated for the treatment of individuals with congenital hemophilia A who have developed inhibitory antibodies (inhibitors) against their human FVIII replacement therapy.  In achieving this milestone, Inspiration has received a $25 million milestone payment from the Ipsen Group (Euronext: IPN; ADR: IPSEY), under a partnership agreement signed with Ipsen in January 2010.  In return, Inspiration has issued Ipsen a convertible note, bringing Ipsen's fully diluted ownership position in Inspiration to 40.7%.

The OBI-1 pivotal clinical study is a prospective, non-randomized, open-label study evaluating the efficacy of OBI-1 for the treatment of serious bleeding episodes, including episodes that are a threat to a patient's life or vital organs. 

Dr. Johnny Mahlangu, MD, Director of the Adult Hemophilia Comprehensive Care Unit at Johannesburg Hospital, and President of the South African Society of Hematology, commented, "There remains a significant unmet medical need when it comes to treating individuals with hemophilia A who have developed inhibitors.  Current therapies do not reach the same level of efficacy as replacement therapy for non-inhibitor patients, leading to potential joint complications, increased risk of bleeding, pain and impact on the patient's quality of life.  Unlike available bypassing agents, OBI-1 facilitates the intrinsic hemostatic pathway, and therefore may allow clinicians to correlate activity and efficacy with FVIII levels (a surrogate for efficacy), enabling them to guide dosing and better predict treatment outcomes.  We are
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
2. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
3. Inspiration for My Sisters Keeper Speaks Out
4. National Expressions of Courage Art Contest Unveils Stories of Inspiration
5. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
6. Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
7. Siemens MAMMOMAT Inspiration Digital Mammography Commercially Available in U.S.
8. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
9. Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B
10. Inspiration Biopharmaceuticals Announces Data from OBI-1 Pivotal-Stage Program in Hemophilia at 23rd ISTH Congress
11. Heskas 2011 "Inspiration in Action" Contest Begins: Support the Veterinary Profession and Help Animals in Need
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... BOTHELL, Wash. and VANCOUVER, British Columbia ... OGXI ), a leader in the development of ... today announced that four trials of its investigational compounds, custirsen ... at the 49 th Annual Meeting of the American ... from May 31 – June 4. ...
(Date:5/21/2013)... Mass. , May 21, 2013  NxStage Medical, ... of innovative dialysis products, today announced that it has ... critical care and in-center products to DaVita, the kidney ... http://photos.prnewswire.com/prnh/20110503/MM94799LOGO ) For the use ... United States , NxStage has executed a second ...
(Date:5/21/2013)... 21, 2013   Regulus Therapeutics Inc . ( ... and development of innovative medicines targeting microRNAs, today announced ... Chief Operating Officer and Executive Vice President, Finance, will ... Annual Healthcare Conference on Wednesday, May 29, 2013 at ... the Westin Boston Waterfront Hotel. The presentation ...
Breaking Medicine Technology:OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 2OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 3OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 4OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 5NxStage Announces New Agreements with DaVita 2Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference 2
... Concord Medical Services Holdings Limited ("Concord Medical" or ... operator of the largest network of radiotherapy and ... it has signed an Memorandum of Understating ("MOU") ... Electric International Operations Company, Inc. and GE Medical ...
... 2011 China Nuvo Solar Energy, Inc. (OTCQB: CNUV) ... with Tandem Receivable Solutions to a western distributorship. Tandem, ... committed to assisting the Company from sales through collections ... Tom Toland, CEO of SurgLine stated, "As business ...
Cached Medicine Technology:Concord Medical and GE Healthcare Sign MOU for Preferred Partnership in China 2China Nuvo Solar Target Acquisition SurgLine Announces Agreement With Western U.S. Distributor 2China Nuvo Solar Target Acquisition SurgLine Announces Agreement With Western U.S. Distributor 3
(Date:5/22/2013)... will publish details of a technique to measure the ... age. The method is demonstrated by the laboratory of Dr. ... Dr. Atzmon hopes that the dissemination of this technique will ... a patients health in relation to other individuals of the ... a technique that measures telomere length. Recently, telomeres have gained ...
(Date:5/22/2013)... (HealthDay News) -- Roughly four in 10 uninsured patients ... (COPD) actually do not have the lung disease, a ... were made based on an evaluation of symptoms, rather ... test known as spirometry, which shows how well a ... air they can exhale and how long that takes. ...
(Date:5/22/2013)... Women,s Hospital (BWH) finds that a genetic risk factor ... may be effective in identifying individuals at risk for ... the American Thoracic Society International Conference and publish online ... on May 22 and will appear in the ... the MUC5B gene is fairly common, pulmonary fibrosis is ...
(Date:5/22/2013)... ─More than 40 percent of patients being treated ... not have the disease, researchers found after evaluating ... for chronic obstructive pulmonary disease. , "While there ... COPD, there has not been a U.S.-based study ... Christian Ghattas, MD., MSc, a second-year medical ...
(Date:5/22/2013)... In the past decade, more than ... with donated uniforms, shoes, balls and other equipment, ... partnering with manufacturers to provide youth with sporting goods. ... million in sports and fitness equipment over 10 years, ... for physical activity. , An inaugural donation of ...
Breaking Medicine News(10 mins):Health News:How healthy are you for your age? 2Health News:COPD May Be Over-Diagnosed Among Uninsured 2Health News:Genetic marker associated with risk for pulmonary fibrosis 2Health News:Study finds COPD is over-diagnosed among uninsured patients 2Health News:Study finds COPD is over-diagnosed among uninsured patients 3Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3
... 10 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... Company 28th Annual Healthcare Conference will be webcast,live ... section of the Company,s,website, http://www.millennium.com ., ... will include an update on VELCADE(R) (bortezomib) for,Injection ...
... March 10 /PRNewswire-FirstCall/,-- The Providence Service Corporation ... a comprehensive behavioral health company, today,announced that ... agreement.,Under the agreement, Providence will become a ... affiliates facilitating,contracting for Providence,s outpatient and home ...
... Web site, Best Branded ... Campaign, WEST CONSHOHOCKEN, Pa., March 10 Cadient ... announced today it has received multiple nominations for the ... at the DTC,National Advertising Awards Dinner on April 17, ...
... Potential to Address Large Acute Pain Prescription Drug ... ... March 10 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) today announced ... for its twice-daily, tramadol-acetaminophen,combination product (study 06CCL3-001)., "Tramadol-acetaminophen combination products ...
... (http://www.NBTY.com ), a leading global manufacturer and marketer ... the,presentation by Harvey Kamil, President and Chief Financial Officer ... New York on Tuesday,March 11, 2008., The presentation ... Company Web,site, http://www.nbty.com on Tuesday, March 11, ...
... Itself by Earning, Microsoft Competencies in Data Management ... ... Ohio, March 10 Antares Management Solutions,a premier servicing ... announced it has attained Gold,Certified Partner status in the ...
Cached Medicine News:Health News:Cowen & Company 28th Annual Healthcare Conference to Webcast Millennium Presentation 2Health News:Providence Service Corporation and UnitedHealth Group Affiliate, OptumHealth Behavioral Solutions, Enter Into Strategic Relationship Agreement 2Health News:Providence Service Corporation and UnitedHealth Group Affiliate, OptumHealth Behavioral Solutions, Enter Into Strategic Relationship Agreement 3Health News:Providence Service Corporation and UnitedHealth Group Affiliate, OptumHealth Behavioral Solutions, Enter Into Strategic Relationship Agreement 4Health News:Cadient Group Receives Multiple Nominations for 2008 DTC National Advertising Awards 2Health News:Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen 2Health News:Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen 3Health News:NBTY to Webcast Presentation at Bank of America Consumer Conference: Announces Preliminary Sales and the Repurchase of 6.1 Million Shares 2Health News:NBTY to Webcast Presentation at Bank of America Consumer Conference: Announces Preliminary Sales and the Repurchase of 6.1 Million Shares 3Health News:Antares Management Solutions Attains Gold Certified Partner Status in Microsoft Partner Program 2Health News:Antares Management Solutions Attains Gold Certified Partner Status in Microsoft Partner Program 3Health News:Antares Management Solutions Attains Gold Certified Partner Status in Microsoft Partner Program 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: